PROJECT 2 : Let's develop Single-Cell precision medicine

Single-cell analysis is at the crossroads of disciplines: biology, physics, mathematics, Big Data, etc. It provides access to the individuality of each cell in its environment. This knowledge makes it possible to better target the specific nature of both normal and pathological cells.

Geneviève Almouzni, Director of the Research Center

Institut Curie wants to have the means to revolutionize cancer treatment in the 21st century by taking part in the advent of this precision cell medicine. For this, Institut Curie has decided to make a major investment in this area by:

• Setting up the first single-cell analysis platform in France (Drop-Seq), in association with Institut Pasteur and ESPCI. It involves three of the Institute's technologies (cytometry, genomics, and bioinformatics) and at least four research units (immunity and cancer, genetics and developmental biology, tumor biology, and nuclear dynamics).
• Recruiting researchers with an "unconventional" profile and multidisciplinary expertise: biology, genetics, immunology, epigenetics, mathematics, physics.
• Developing analysis capacities in bioinformatics and mathematical modeling.

IMPACTS:

• Adaptation of the treatment of each patient according to the cellular profile of each tumor for better results
• Anticipation of recurrence for better patient care
• Development of new treatments through the identification of new therapeutic targets

IMPACTS:

• Adaptation of the treatment of each patient according to the cellular profile of each tumor for better results
• Anticipation of recurrence for better patient care
• Development of new treatments through the identification of new therapeutic targets

For more information